Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects

James G. Jackson, Patricia St. Clair, Mark X. Sliwkowski, Michael G. Brattain

Research output: Contribution to journalArticle

86 Scopus citations

Fingerprint Dive into the research topics of 'Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects'. Together they form a unique fingerprint.

Medicine & Life Sciences